A safe, effective treatment for severe pregnancy sickness remains difficult for many women to access on the NHS, despite decades of clinical use. Diclegis, a combination of doxylamine and pyridoxine (vitamin B6), has been prescribed since the 1970s and carries no proven risk to fetal development. Yet NHS trusts vary wildly in whether they stock it or recommend alternatives.
The inconsistency stems from funding gaps and formulary restrictions. Some trusts classify the medication as low priority, forcing pregnant women with hyperemesis gravidarum, a severe form of morning sickness, to seek private prescriptions or rely on off-label treatments with less clinical support. This creates a postcode lottery where geography determines treatment access rather than medical need.
BBC Health investigation reveals that women often endure weeks of debilitating nausea, vomiting, and dehydration before escalating to hospital care, which costs the NHS far more than preventative medication would. Pregnancy sickness affects up to 80 percent of pregnant women, with about 1-2 percent experiencing hyperemesis gravidarum severe enough to cause hospitalization.
The drug's availability problem reflects broader NHS resource allocation challenges. Without centralized guidance mandating Diclegis coverage, individual trusts make cost-benefit calculations based on local budgets. Meanwhile, women pay hundreds of pounds privately or suffer untreated symptoms that impact their quality of life and fetal nutrition.
Medical professionals argue the current system lacks logic. A thirty-pound prescription costs significantly less than emergency interventions, yet bureaucratic inertia keeps the drug off many formularies. Advocates push for standardized NHS access to Diclegis as part of routine pregnancy care, not luxury treatment rationed by postcode.